"Virginia Kaklamani, MD @VKaklamani @UTHealthsaMDA discusses new data from #ASCO23 FDA-approved #Elacestrant for #breastcancer with ESR1-mutations. The EMERALD study results, announced by the #Menarini @Stemline Therapeutics, show PFS benefits. 🔬[video] https://t.co/9fioU5hFAU" (@oncologytube)

The post-CDK space has long been an unmet need in breast oncology, and it still is. Yet, decades of research are finally converging on novel treatments for our pts, including elacestrant and likely soon capivasertib. Thanks to @OncLive for this interview! https://t.co/LVLYkTCud2 (@PTarantinoMD)

During this event, Claudine Isaacs, MD, discussed the role of #elacestrant for patients with ER+, HER2-negative breast cancer. #bcsm | @LombardiCancer @claudine_isaacs https://t.co/HV86Y63CKw (@TargetedOnc)

Check out Dr. Erica Mayer @elmayermd @DFCI_BreastOnc discussing #ASCO23 evERA #BreastCancer Phase 3 Study - Giredestrant + Everolimus vs. Exemestane + Everolimus in Pts With ER+/HER2- Locally Advanced or Metastatic BC #bcsm https://t.co/1F9i6Kclgx (@Sameh_VuMedi)

2/6 #TumorBoardTuesday ThursCase🎀 Take🏠msgs: #metastatic HR+ #breastcancer ✅ NGS is 🗝️ in ER+ mBC on CDK4/6i ✅ ESR1 mut➡️Elacestrant ✅ No ESR1 mutation, but PIK3CA mut, consider 🎯tx, beware side effects 📚Here’s @ilanaschlam @drsarahsam’s thread https://t.co/DcA8w8ofI9 (@JohnEbbenMDPhD)

Just last week, I asked Sacha (Howell) when was dad retiring? A giant in endocrine therapy for breast cancer! A close encounter as my research (on Faslodex) examiner! What a long fulling career! Congratulations, thanks and best wishes, Prof Anthony Howell. (@iBreastSurgeon)

11/17 #TumorBoardTuesday #SABCS22 ✨EMERALD✨ post hoc analysis: ❗without ESR1 mutations + PD <6mos on CDK4/6 inhibitor = elacestrant ⬆️ PFS (5.3 vs 1.9m) ❗without ESR1 mutations + PD >6mos on CDK4/6 inhibitor = elacestrant ↔️ PFS (1.9 vs 2 m) #ASCO23 #VirginiaKalkamani (@IlanaSchlam)

New📰published: AMEERA-3: Randomized Phase II Study of Amcenestrant Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. @stolaney1 and colleagues. https://t.co/QqL6DtT4C7 (@DFCI_BreastOnc)

Findings from a subgroup analysis of the phase 3 EMERALD trial demonstrated elacestrant elicited prolonged PFS vs SOC in ER+, HER2– non-detected ESR1 mutated breast cancer who experienced disease progression. @VKaklamani #ASCO23 #bcsm https://t.co/lPcacbcFRo (@OncLive)

Capivasertib + fulvestrant has been granted @FDAOncology priority review. #bcsm https://t.co/wBnOSMFNEH (@stage4kelly)

Recently published📰: A phase I trial of #palbociclib and #bosutinib with #fulvestrant in patients with metastatic HR+ HER2- #BreastCancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor by @FilipaLynce @EDBarrowsMD @juliecollinsmd @claudine_isaacs @ppohlmann_ et al (@DFCI_BreastOnc)

Check out Dr. Virginia Kaklamani @VKaklamani @UTHealthSAMDA discussing #ASCO23 Oral #Elacestrant vs. SOC in ER+/HER2- Advanced or #mBC w/o Detectable #ESR1 Mutation (EMERALD) - Subgroup Analysis by Prior Duration of CDK4/6i + ET #bcsm #breastcancer #cdk46 https://t.co/SDTuK9Jxot (@Sameh_VuMedi)

Findings from a subgroup analysis of the phase 3 EMERALD trial demonstrated elacestrant elicited prolonged PFS vs SOC in ER+, HER2– non-detected ESR1 mutated breast cancer who experienced disease progression. @VKaklamani @ASCO #ASCO23 #bcsm https://t.co/IDnlmEDmWA (@OncLive)

Single agent Fulvestrant post CDK4/6 needs to be retired. And we need to stop using it as a comparator backbone in trials. It’s not good for patients. #onctwitter #bcsm #ASCO2023 (@Dr_RShatsky)

Leonardo study Lerociclib ➕ Fulvestrant comprd to Fulv s/p progression in 1st line 📌 PFS improved with Lerociclib plus Fulvestrant ➡️mPFS of 11.5 vs. 5.9mos 📌will this improve our global access with a more affordable CDK4/6i @maryam_lustberg . @OncoAlert #ASCO2023 #bcsm (@MridulaGeorgeMD)

📊Metastatic Breast Cancer Poster Session: evERA #BreastCancer: Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients with ER+, HER2– locally advanced or #MetastaticBreastCancer. @elmayermd @stolaney1 @hoperugo @breastoncdoc https://t.co/o61r28PUFH (@DFCI_BreastOnc)

Subgroup Analysis Demonstrates Promising Activity With Elacestrant in ER+/HER2- Advanced or Metastatic Breast Cancer @VKaklamani @UTHealthSA @ASCO #ASCO23 https://t.co/rmYqTciu61 (@OncLive)

#ASCO23 Selective Estrogen Receptor Downregulators (SERDs) in Breast Cancer: Where do We Stand? Summary of efficacy data for new SERDs👇 From the great presentation by Dr @CHernandoM @ASCO @OncoAlert https://t.co/qcfda6CVDu (@dr_yakupergun)

Lerociclib/Fulvestrant May Reduce Risk of Disease Progression in Advanced HR-Positive/HER2-Negative Breast Cancer https://t.co/TWzsHInxAr @ASCO #ASCO23 @glopesMD (@GlopesMd)

The Oncology Brothers and Virginia Kaklamani, MD, DSc, give an overview on elacestrant and the EMERALD trial for patients with ER+, HER2- advanced breast cancer. #bcsm | @OncBrothers @UPMCHillmanCC @WilmotCancer @VKaklamani https://t.co/ssxhCMictv (@TargetedOnc)

On the 👠 of @ASCO’s ESR1 rec, we 🗣 #Elacestrant and how it fits in our daily practice for HR+ #breastcancer with @VKaklamani Full Int: - https://t.co/Q7GEc99kIb - https://t.co/OdMGRvntR0 - Also on the “Oncology Brothers” podcast #bcsm #OncTwitter #MedTwitter @TargetedOnc (@OncBrothers)

Patient-reported outcomes among patients who received elacestrant were consistent with other endocrine therapies. #ESMOBreast23 #oncology #nursing #bcsm #breastcancer @myESMO @JavierCortesMD https://t.co/k8PXHlzOLd (@OncNursingNews)

PRO's demonstrated that elacestrant maintained the quality of life for patients with metastatic breast cancer for at least 6 treatment cycles. @JavierCortesMD @VHIO @myESMO #ESMOBreast23 #bcsm https://t.co/hvdSbyHiWW (@OncLive)

Elacestrant maintained the quality of life for patients with metastatic breast cancer for at least 6 treatment cycles, according to patient reported outcomes. @JavierCortesMD @VHIO @myESMO #ESMOBreast23 #bcsm https://t.co/BunwVtbTc8 (@OncLive)

According to Erika Hamilton#Elacestrant appears well tolerated #ESMO23 #BreastCancer (@renatehaidinger)

Our great @JavierCortesMD presenting at #ESMObreast23 the #PRO data from #EMERALD trial that tested the oral SERD #elacestrant in patients with endocrine resistant #BreastCancer @ErikaHamilton9 @myESMO @OncoAlert #bcsm (@matteolambe)

Further convincing efficacy data from the #CAPItello291 trial presented at #ESMObreast23: consistent PFS benefit across all subgroups of patients with endocrine resistant #BreastCancer receiving #capivasertib added to #fulvestrant @myESMO @OncoAlert @ErikaHamilton9 #bcsm (@matteolambe)

MSK Discovery of ESR1 Gene Mutation Leads to Approval of Breast Cancer Drug Elacestrant https://t.co/ah7q7hoJXx (@weldeiry)

Dr Erica Mayer (@elmayermd) is a co-investigator on SERENA-6 (NCT04964934), an ongoing randomized, double-blind, phase III trial of camizestrant + CDK4/6i in ESR1-mutant HR+/HER2-negative advanced breast cancer during first-line treatment. Trial protocol: https://t.co/bIeMClWmjx (@DFCI_BreastOnc)

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line trea… https://t.co/kQji0I64pj Very nice ongoing study, reminiscent of the PADA 1 trial, but with a better (oral) SERD. I believe, however, that an arm is missing.... (@FilippoMontemu1)

This is the updated #algorithm we used during our discussion w/ @DrGattiMays for HR+ #BreastCancer #sacituzumab (or is it “sassy toucan”) #elacestrant #TDxD #ERPositive #bcsm #OncTwitter #OncEd #MedTwitter @OncoAlert https://t.co/fslueYjU6H (@OncBrothers)

We need to know whether selective estrogen receptor degraders (SERDs) require concurrent LHRH agonists in premenopausal females & males. It stands to reason that they may not, & it would be great to spare patients that toxicity. Unmet need, easy to study 👀 #bcsm #OncTwitter (@tmprowell)

In this 1st-in-human phase 1b study, the pan-AKT inhibitor vevorisertib as monotherapy or in combo w/ paclitaxel or fulvestrant had a generally manageable safety profile in pats w/ PIK3CA/AKT/PTEN-mutated advanced solid tumors. 🔗 https://t.co/OrAWPs2Nnf CC: @VivekSubbiah (@JournalCancer)

A new development for breast cancer patients! A selective estrogen receptor degrader (SERD) called Elacestrant has been approved by the FDA to treat breast cancer. @LaVoieGroup @VKaklamani #Orserdu Listen and Share the Audio Podcast Here: https://t.co/sHYdfsps0P (@oncologytube)

Tomorrow night is cancer talk 3/5 for the month of March for me! Will be speaking at the Del Mar Hilton on Oral Selective Estrogen Receptor Degraders (oral SERDs) for OncLive. @OncLiveSOSS @OncLive #bcsm @UCSDCancer (@Dr_RShatsky)

New development for breast cancer patients! A selective estrogen receptor degrader (SERD) called Elacestrant has been approved by the FDA to treat breast cancer by Dr. Virginia Kaklamani @LaVoieGroup @VKaklamani #Orserdu Read and Share the Article Here: https://t.co/siOrOhVz3Y (@oncologytube)

WATCH: @VKaklamani reviews updated results and clinical implications of the phase 3 EMERALD trial evaluating elacestrant in patients with ER+/HER2- metastatic breast cancer presented at the 2022 SABCS. #bcsm #oncology https://t.co/HBLucV9OCS (@OncLive)

21/24 #TumorBoardTuesday #BreastCancer ✨EMERALD✨ 🎉 Based on data, elacestrant was approved on Jan 27, 2023 for treatment of patients with ESR1-mutant HR+ breast cancer who have progressed to at least 1L of endocrine treatment 📚 https://t.co/DY4VIO4Smo (@PTarantinoMD)

New data supporting a deeper #ESR1 variant characterization in #BreastCancer. Y537S is resistant to #SERD #SERM due to stable conformation and activity. L536 shows varying sensitivity, greatest resistance: AZD9833 GDC-0810 RAD1901 #PrecisionMedicine #bcsm https://t.co/5llI1gngbs (@LGerratana)

Interested in learning how to integrate Elacestrant in the post-CDK4/6 setting?Check out this Editorial by @MarlaLipsycMD and @stolaney1 in Annals of Oncology https://t.co/omrENS2gl7 #bcsm (@Annals_Oncology)

Data at #SABCS22 showed that a major PFS improvement with elacestrant was seen among ESR1m tumors. The benefit further increased if there was a prolonged benefit from prior CDK4/6i Based on these data, elacestrant was approved by the @FDAOncology on Jan 27 for ESR1m HR+ MBC 6/ (@PTarantinoMD)

WATCH: @VKaklamani, of @UTHealthSA, discusses the evolution of oral selective estrogen receptor degraders in estrogen receptor-positive breast cancer. #bcsm #oncology https://t.co/LZEgCdDY5I (@OncLive)